The VMAT-2 inhibitor tetrabenazine alters effort-related decision making as measured by the T-maze barrier choice task: Reversal with the adenosine A2A antagonist MSX-3 and the catecholamine uptake blocker bupropion

Samantha E. Yohn, Christian Thompson, Patrick A. Randall, Christie A. Lee, Christa E. Müller, Younis Baqi, Mercè Correa, John D. Salamone

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Rationale: Depressed people show effort-related motivational symptoms, such as anergia, retardation, lassitude, and fatigue. Animal tests can model these motivational symptoms, and the present studies characterized the effort-related effects of the vesicular monoamine transport (VMAT-2) inhibitor tetrabenazine. Tetrabenazine produces depressive symptoms in humans and, at low doses, preferentially depletes dopamine. Objectives: The current studies investigated the effects of tetrabenazine on effort-based decision making using the T-maze barrier task. Methods: Rats were tested in a T-maze in which the choice arms of the maze contain different reinforcement densities, and under some conditions, a vertical barrier was placed in the high-density arm to provide an effort-related challenge. The first experiment assessed the effects of tetrabenazine under different maze conditions: a barrier in the arm with 4 food pellets and 2 pellets in the no barrier arm (4-2 barrier), 4 pellets in one arm and 2 pellets in the other with no barrier in either arm (no barrier), and 4 pellets in the barrier arm with no pellets in the other (4-0 barrier). Results: Tetrabenazine (0.25-0.75 mg/kg IP) decreased selection of the high cost/high reward arm when the barrier was present, but had no effect on choice under the no barrier and 4-0 barrier conditions. The effects of tetrabenazine on barrier climbing in the 4-2 condition were reversed by the adenosine A2A antagonist MSX-3 and the catecholamine uptake inhibitor and antidepressant bupropion. Conclusions: These studies have implications for the development of animal models of the motivational symptoms of depression and other disorders.

Original languageEnglish
Pages (from-to)1313-1323
Number of pages11
JournalPsychopharmacology
Volume232
Issue number7
DOIs
Publication statusPublished - 2015

Fingerprint

Tetrabenazine
Bupropion
Adenosine
Catecholamines
Decision Making
Fatigue
Depression
Reward
Antidepressive Agents
Dopamine
Animal Models
Costs and Cost Analysis
Food

Keywords

  • Accumbens
  • Anergia
  • Behavioral activation
  • Depression
  • Dopamine
  • Fatigue
  • Motivation
  • Reward

ASJC Scopus subject areas

  • Pharmacology

Cite this

The VMAT-2 inhibitor tetrabenazine alters effort-related decision making as measured by the T-maze barrier choice task : Reversal with the adenosine A2A antagonist MSX-3 and the catecholamine uptake blocker bupropion. / Yohn, Samantha E.; Thompson, Christian; Randall, Patrick A.; Lee, Christie A.; Müller, Christa E.; Baqi, Younis; Correa, Mercè; Salamone, John D.

In: Psychopharmacology, Vol. 232, No. 7, 2015, p. 1313-1323.

Research output: Contribution to journalArticle

Yohn, Samantha E. ; Thompson, Christian ; Randall, Patrick A. ; Lee, Christie A. ; Müller, Christa E. ; Baqi, Younis ; Correa, Mercè ; Salamone, John D. / The VMAT-2 inhibitor tetrabenazine alters effort-related decision making as measured by the T-maze barrier choice task : Reversal with the adenosine A2A antagonist MSX-3 and the catecholamine uptake blocker bupropion. In: Psychopharmacology. 2015 ; Vol. 232, No. 7. pp. 1313-1323.
@article{e7be6cf31b614ad5be51c989c7ef37ea,
title = "The VMAT-2 inhibitor tetrabenazine alters effort-related decision making as measured by the T-maze barrier choice task: Reversal with the adenosine A2A antagonist MSX-3 and the catecholamine uptake blocker bupropion",
abstract = "Rationale: Depressed people show effort-related motivational symptoms, such as anergia, retardation, lassitude, and fatigue. Animal tests can model these motivational symptoms, and the present studies characterized the effort-related effects of the vesicular monoamine transport (VMAT-2) inhibitor tetrabenazine. Tetrabenazine produces depressive symptoms in humans and, at low doses, preferentially depletes dopamine. Objectives: The current studies investigated the effects of tetrabenazine on effort-based decision making using the T-maze barrier task. Methods: Rats were tested in a T-maze in which the choice arms of the maze contain different reinforcement densities, and under some conditions, a vertical barrier was placed in the high-density arm to provide an effort-related challenge. The first experiment assessed the effects of tetrabenazine under different maze conditions: a barrier in the arm with 4 food pellets and 2 pellets in the no barrier arm (4-2 barrier), 4 pellets in one arm and 2 pellets in the other with no barrier in either arm (no barrier), and 4 pellets in the barrier arm with no pellets in the other (4-0 barrier). Results: Tetrabenazine (0.25-0.75 mg/kg IP) decreased selection of the high cost/high reward arm when the barrier was present, but had no effect on choice under the no barrier and 4-0 barrier conditions. The effects of tetrabenazine on barrier climbing in the 4-2 condition were reversed by the adenosine A2A antagonist MSX-3 and the catecholamine uptake inhibitor and antidepressant bupropion. Conclusions: These studies have implications for the development of animal models of the motivational symptoms of depression and other disorders.",
keywords = "Accumbens, Anergia, Behavioral activation, Depression, Dopamine, Fatigue, Motivation, Reward",
author = "Yohn, {Samantha E.} and Christian Thompson and Randall, {Patrick A.} and Lee, {Christie A.} and M{\"u}ller, {Christa E.} and Younis Baqi and Merc{\`e} Correa and Salamone, {John D.}",
year = "2015",
doi = "10.1007/s00213-014-3766-0",
language = "English",
volume = "232",
pages = "1313--1323",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "7",

}

TY - JOUR

T1 - The VMAT-2 inhibitor tetrabenazine alters effort-related decision making as measured by the T-maze barrier choice task

T2 - Reversal with the adenosine A2A antagonist MSX-3 and the catecholamine uptake blocker bupropion

AU - Yohn, Samantha E.

AU - Thompson, Christian

AU - Randall, Patrick A.

AU - Lee, Christie A.

AU - Müller, Christa E.

AU - Baqi, Younis

AU - Correa, Mercè

AU - Salamone, John D.

PY - 2015

Y1 - 2015

N2 - Rationale: Depressed people show effort-related motivational symptoms, such as anergia, retardation, lassitude, and fatigue. Animal tests can model these motivational symptoms, and the present studies characterized the effort-related effects of the vesicular monoamine transport (VMAT-2) inhibitor tetrabenazine. Tetrabenazine produces depressive symptoms in humans and, at low doses, preferentially depletes dopamine. Objectives: The current studies investigated the effects of tetrabenazine on effort-based decision making using the T-maze barrier task. Methods: Rats were tested in a T-maze in which the choice arms of the maze contain different reinforcement densities, and under some conditions, a vertical barrier was placed in the high-density arm to provide an effort-related challenge. The first experiment assessed the effects of tetrabenazine under different maze conditions: a barrier in the arm with 4 food pellets and 2 pellets in the no barrier arm (4-2 barrier), 4 pellets in one arm and 2 pellets in the other with no barrier in either arm (no barrier), and 4 pellets in the barrier arm with no pellets in the other (4-0 barrier). Results: Tetrabenazine (0.25-0.75 mg/kg IP) decreased selection of the high cost/high reward arm when the barrier was present, but had no effect on choice under the no barrier and 4-0 barrier conditions. The effects of tetrabenazine on barrier climbing in the 4-2 condition were reversed by the adenosine A2A antagonist MSX-3 and the catecholamine uptake inhibitor and antidepressant bupropion. Conclusions: These studies have implications for the development of animal models of the motivational symptoms of depression and other disorders.

AB - Rationale: Depressed people show effort-related motivational symptoms, such as anergia, retardation, lassitude, and fatigue. Animal tests can model these motivational symptoms, and the present studies characterized the effort-related effects of the vesicular monoamine transport (VMAT-2) inhibitor tetrabenazine. Tetrabenazine produces depressive symptoms in humans and, at low doses, preferentially depletes dopamine. Objectives: The current studies investigated the effects of tetrabenazine on effort-based decision making using the T-maze barrier task. Methods: Rats were tested in a T-maze in which the choice arms of the maze contain different reinforcement densities, and under some conditions, a vertical barrier was placed in the high-density arm to provide an effort-related challenge. The first experiment assessed the effects of tetrabenazine under different maze conditions: a barrier in the arm with 4 food pellets and 2 pellets in the no barrier arm (4-2 barrier), 4 pellets in one arm and 2 pellets in the other with no barrier in either arm (no barrier), and 4 pellets in the barrier arm with no pellets in the other (4-0 barrier). Results: Tetrabenazine (0.25-0.75 mg/kg IP) decreased selection of the high cost/high reward arm when the barrier was present, but had no effect on choice under the no barrier and 4-0 barrier conditions. The effects of tetrabenazine on barrier climbing in the 4-2 condition were reversed by the adenosine A2A antagonist MSX-3 and the catecholamine uptake inhibitor and antidepressant bupropion. Conclusions: These studies have implications for the development of animal models of the motivational symptoms of depression and other disorders.

KW - Accumbens

KW - Anergia

KW - Behavioral activation

KW - Depression

KW - Dopamine

KW - Fatigue

KW - Motivation

KW - Reward

UR - http://www.scopus.com/inward/record.url?scp=84924898142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924898142&partnerID=8YFLogxK

U2 - 10.1007/s00213-014-3766-0

DO - 10.1007/s00213-014-3766-0

M3 - Article

C2 - 25323625

AN - SCOPUS:84924898142

VL - 232

SP - 1313

EP - 1323

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 7

ER -